American heart journal
-
American heart journal · Aug 2002
Randomized Controlled Trial Comparative Study Clinical TrialRandomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use. Its antiplatelet action appears to be mainly related to inhibition of intracellular phosphodiesterase activity. Recently, cilostazol has been used for antiplatelet therapy after coronary stent implantation. However, its evaluation has not been established yet. ⋯ Aspirin plus cilostazol therapy may be an effective regimen for prevention of not only stent thrombosis but also restenosis.